Apogee Therapeutics, Inc. - Common Stock (APGE)

The recent rally could pave the way for "sell the news" volatility, but don't let this scare you out of a long-term position.

AbbVie has an attractive 2.7% yield, a solid pharmaceutical business, and is clearly focused on its dividend.

It looks like a great buy-and-hold option.

There's no need to panic.

They can help stabilize your portfolio in these otherwise volatile times.

Henderson's disposition included a 20,000-share open-market sale and a 75,046-share charitable gift.

AbbVie inherited its status as a Dividend King, but it is building a strong foundation to continue the dividend streak.

This dividend ETF's focus beyond yield continues to pay off for investors.

AbbVie knows how to plan ahead.

An intriguing acquisition could bring exciting new drugs into the medicine maker's development pipeline.

The company is already renowned by many as a giant in the segment.

On June 22, 2026, Apogee Therapeutics shares surged as investors reacted to AbbVie's proposed acquisition terms.

Apogee Therapeutics (NASDAQ:APGE) executives outlined plans to advance zumilokibart, the company’s IL-13-targeting antibody, into late-stage development for atopic dermatitis while expanding the program into asthma and eosinophilic esophagitis, during a Goldman Sachs discussion hosted by lead biotec

Apogee Therapeutics (NASDAQ:APGE) executives said the company is preparing to move its lead drug candidate, zumilokibart, into Phase 3 testing later this year after reporting Phase 2b data in atopic dermatitis and securing a major financing agreement with Blackstone. Speaking at a Jefferies-hosted

INDIANAPOLIS – In a move that has left some retail investors scratching their heads, shares of Eli Lilly and Company (NYSE:LLY) have trended lower this week, despite the pharmaceutical giant releasing stellar long-term clinical data for its atopic dermatitis (eczema) treatment, Ebglyss. The disconnect between the laboratory and the trading

This biotech innovator in immunology reported a notable insider sale as its stock outperformed and drug development efforts continue.

On March 23, 2026, the small-cap heavy Russell 2000 Index surged by a definitive 3.0%, soundly outperforming the S&P 500 and the Nasdaq Composite in a session characterized by aggressive "risk-on" buying. This sharp technical breakout represents a significant turning point for small-cap equities, which had spent the